Combination therapy of pulmonary metastasised gynaecological cancer with inhalative IL-2 - Results of a feasibility study;Additive immuntherapie bei pulmonal metastasierten gynakologischen karzinomen mit inhalativem interleukin-2 - Ergebnisse der feasibility studie

Geburtshilfe und Frauenheilkunde

Volumn 59, Issue 4, 1999, Pages 157-162

  Petzoldt, B ^a   Prietl, C ^b   Kupka, M ^b   Kohler S ^b   Krebs, D ^b   Wagner, U ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; RECOMBINANT INTERLEUKIN 2; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG METASTASIS; OVARY CARCINOMA; RADIODIAGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032901763     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-1999-14180     Document Type: Article

References (30)

1. Atzpodien, J., A. Körfer, C. R. Franks, H. Poliwoda et al.: Home Therapy with Recombinant Interleukin-2 and Interferon-alpha2b in Advanced Human Malignancies. Lancet 335 (1990) 1509.
2. Aulitzky, W. E., M. Kessler, M. Wilhelm, E. Huland, A. Thews, C. Peschel, C. Huber, J. Lorenz: Aerosolized Natural Interleukin 2 for Treatment of Advanced Malignancy: Results of a Phase 1 Trial. Ann. Hematol. 66 (Suppl. 2) (1993) A109.
3. Atzpodien J., H. Kirchner, H. Poliwoda: Interleukin-2-haltige ambulante Therapie des metastasierenden Nierenzellkarzinoms. Medizinische Klinik, 91. Jahrgang (1996) 38-41.
4. Baxevanis, C. N. et al.: Elevated Prostaglandin E2 Production by Monocytes is Responsible for the Depressed Levels of Natural Killer and Lymphokine Activated Killer Cell Funktion in Patients with Breast Cancer. Cancer 72 (1993) 491-501.
5. Doyle, M. V., M. T. Lee, S. Fong: Comparison of the Biological Activities of Human Recombinant Interleukin-2 and Native Interleukin-2. J. Biol. Response Modif. 316 (1985) 96-109.
6. Enk, A., D. Nashan, J. Knop: Therapie von Lungenmetastasen des malignen Melanoms mit inhalativem Interleukin-2. Hautarzt, Springer Verlag 48 (1997) 894-896.
7. Gaede, K. I., G. Zissel, U. Schwulera, W. G. Struff, J. Lorenz, W. E. Aulitzky, P. Zipfel, S. Schrum, M. Schlaak, C. Huber, J. Muller-Quernheim: Spontaneous and Interleukin-2-modulated Cytokine Release by Bronchoalveolar Cells in Pulmonary Malignancy. Europ. Cytokine Netw. 8 (4) (1997) 395-400.
8. Hänninen, E. L., H. Kirchner, J. Atzpodien: Interleukin-2 based home therapy of metastatic renal cell carcinoma. Risks and Benefits in 215 Consecutive Single Institution Patients. J. Urol. 155 (1996) 19-25.
9. Heinzer, H., E. Huland: Inhalation of Recombinant Interleukin-2 (rIL-2) Combined with Low Dose Sytemic Cytokine is Highly Effective in Patients with Pulmonary Metastatic Renal Cell Carcinoma. Abstracts of the Eight International Hamburg Symposium on Tumor Markers, 3-5 December 1995 (abstract 163).
10. Huland, E., H. Heinzer, T. S. Mir, H. Huland: Inhaled Interleukin-2 Therapy in Pulmonary Metastatic Renal Cell Carcinoma. Six Years of Experience. Cancer J. from Scientific American (Vol. 3) (Suppl. 1) (1997).
11. Huland, E., H. Heinzer, H. Huland: Inhaled lnterleukin 2 in Combination with Low Dose Systemic Interleukin-2 and Interferon alpha in Patients with Pulmonary Metastatic Renal Cell Carcinoma: Effectiveness and Toxicity of Mainly Local Treatment. J. Cancer Res. Clin. Oncol. 120 (1994) 121-128.
12. Huland, E., H. Huland, H. Heinzer: Interleukin-2 by Inhalation: Local Therapy for Metastatic Renal Cell Carcinoma. J. Urol. 147 (1992) 344-348.
13. Kato, K. et al.: Purification and Partial Sequence Analysis of Human Interleukin 2 Derived from Peripheral Blood Leukocytes. Biochem. Biophys. Res. Commun. 127 (1985) 182-190.
14. Khanna, C., P. M. Anderson, D. E. Hasz, E. Katsanis, M. Neville, J. S. Klausner: Interleukin-2-Liposome Inhalation Therapy is Safe and Effective for Dogs with Spontaneous Pulmonary Metastases. Cancer 79 (7) (1997) 1409-1414.
15. Khanna, C., D. E. Hasz, J. S. Klausner, P. M. Anderson: Aerosol Delivery of Interleukin 2 Liposomes is Nontoxic and Biologically Effective: Canine Studies. Clin. Cancer Res. Vol. 2 (1996) 721-734.
16. Konjevic, G. et al.: Stage Dependance of NK Cell Activity and its Modulation by Interleukin-2 in Patients with Breast Cancer. Neoplasma 40 (2) (1993) 81-85.
17. Konrad, M. W. et al.: Pharmakokinetics of Recombinant Interleukin-2 in Humans. Cancer Res. 50 (1990) 2009-2017.
18. Lorenz, J., K. Wilhelm, M. Kessler, C. Peschel, U. Schwulera, R. Lissner, W. G. Struff, E. Huland, C. Huber, W. E. Aulitzky: Phase I Trial of Inhaled Natural Interleukin 2 for Treatment of Pulmonary Malignancy: Toxicity, Pharmacokinetics and Biological Effects. Clin. Cancer Res. (Vol. 2) (1996) 1115-1122.
19. Lissoni, B. et al.: Lower Survival in Metastatic Cancer patients with Reduced Interleukin-2 Blood Concentrations. Oncology 48 (1991) 125-127.
20. Lissoni, B. et al.: Weekly Epirubicin plus Low Dose Interleukin-2 Subcutaneous Therapy in Breast Cancer: Preliminary Immunobiological Results. J. Biol. Regul. Homeosat. Agents Apr-Jun 8 (2) (1994) 53-55.
21. Liu, D. L. et al.: Repeated Immunotherapy using Intratumoral Injection with Recombinant Interleukin-2 and Tumorinfiltrating Lymphocytes Inhibits Growth of Breast Cancer and Induces Apoptosis of Tumour Cells. Cancer-Lett. Jun 5; 103 (2) (1996) 131-136.
22. Lotze, M. T. et al.: Clinical Effects and Toxicity of Interleukin-2 in Patients with Cancer. Cancer 58 (1985) 2764-2772.
23. Proleukin Produktmonographie Chiron GmbH, Ratingen.
24. Rosenberg, S. A., E. A. Grim, M. Mc Grogan et al.: Biological Activity of Recombinant Human Interleukin 2 Produced by Eschericia Coli. Science 223 (4643) (1984) 1412-1414.
25. Rosenberg, S. A.: Immunotherapy of Cancer by Systemic Administration of Lymphoid Cells plus Interleukin-2. J. Biol. Response Modif. 3 (1984) 501-511.
26. Rosenberg, S. A., P. Spiess, R. Lafreniere: A New Approach to the Adoptive Immunotherapy with Tumorinfiltrating Lymphocytes. Science 233 (1986) 1318-1321.
27. Rosenberg, S. A., J. C. Yang, S. L. Topalian, S. L. Schwartzentruber, D. J. Weber, J. S. Parkinson, C. A. Seipp, J. H. Eihorn, D. E. White: Treatment of 283 Patients With Metastatic Melanoma or Renal Cell Carcinoma Using High Dose Bolus Interleukin-2. J. Amer. Med. Assn. 271 (1994) 907-913.
28. Siegal, J., R. Puri: Interleukin Toxicity. J. Clin. Oncol. 9 (1991) 694-704.
29. West, W. H., K. W. Tauer, J. R. Yannli et al.: Constant Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer. New Engl. J. Med. 316 (1987) 898-905.
30. Yamasaki, S. et al.: Relationship Between Immunological Parameters and Survival of Patients with Liver Metastases from Breast Cancer given Immunochemotherapy. Breast Cancer Res. Treatment 26 (1993) 55-65.